LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The heavy selling pressure might have exhausted for HilleVax (HLVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESSWIRE / July 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
NEW YORK CITY, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.